Aptus Clinical has been appointed full service clinical CRO partner by Artelo Biosciences Inc. (through their fully owned UK subsidiary, Trinity R&D Ltd).
Aptus Clinical will deliver the upcoming Phase 1B/2A trial of Artelo Bioscience’s synthetic cannabinoid, ART27.13, in testing the cannabinoid in patients with cancer associated weight loss. This latest agreement builds on an earlier research and development partnership agreement, where Aptus successfully designed and supported the critical path pre-clinical experiments and completed key clinical strategy and planning activities for Artelo.
Andrew Yates, ART27.13 Project Director at Trinity R&D, said: “The depth and breadth of experience that our Aptus colleagues have brought to this project and their flexible collaborative approach has been key in helping us achieve this significant project milestone for ART27.13.
“We look forward to continuing to work with Aptus and our investigators in testing the clinical utility of ART27.13 in patients with cancer associated weight loss.”
Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences, said: “Aptus Clinical have approached the inevitable challenges associated with any drug project in a fully supportive and flexible way with a total focus on doing the right things to move the project forward. We look forward to continuing our collaboration Aptus on this next phase of the ART27.13 journey.”
Steve McConchie, Chief Executive Officer of Aptus Clinical, added: “Cancer related anorexia affects about 60% of advanced cancer patients and is an area where new treatment options are desperately needed. As a full-service clinical CRO focused on transforming promising projects into valued medicines we are honoured to have been selected to deliver a trial that is so important for both Artelo and patients with cancer.”